• Evofem Biosciences swung to third-quarter 2026 net income attributable to common stockholders of $865,000 from a year-earlier loss.
• Net sales fell 7% year-over-year to $4.63 million, primarily due to lower PHEXX ex-factory sales.
• Restricted cash and cash equivalents dropped 45% to $317,000 at September 30, 2026, from December 31, 2025.
• A second pharmaceutical manufacturer was contracted to produce PHEXX, aimed at enhancing manufacturing flexibility and reducing costs.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Evofem Biosciences Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-26-051806), on November 13, 2026, and is solely responsible for the information contained therein.